Excel Conference is announcing "Cancer Science and Therapeutics (CST) 2021," to be held in Madrid, Spain during March 26, 27 2021. CST 2021 Madrid, will provide a stimulating scientific environment and a platform for the participants to exchange ideas, establish research collaboration and networking. The scientific planning committee takes great pleasure in welcoming clinicians, academic scientists, researchers, young investigators, students, and industry to CST 2021 Madrid.
CST 2021 Madrid conference will comprise of world-class Keynote Speakers, Workshops, Symposia, Exhibitors, Poster Presentations, Panel discussions and talks by clinicians, scientists and industry of national and international repute together with young investigators and student trainees. The scientific sessions offer researchers, students, industry and health care professionals with unique opportunity to share ideas, acquire knowledge and learn about the recent advances in the areas of Medical Oncology, Cancer Research, Therapeutics, and Cancer Biology.
The purpose of CST 2021 Madrid conference is to promote interest, stimulate research, and promulgate information on all aspects of cancer. Please join with your colleagues in Orlando, USA to learn about the latest advances in cancer drug development and project management challenges across Oncology, Immuno-Oncology, and Immunotherapy and learn what has become the most research-intensive therapeutic area in drug development. Hear from renowned experts on what is being successful in this challenging area of cancer.
The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025
The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. On the basis of drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy, and others. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.
Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
According to drug class type, the targeted therapy segment occupied the largest oncology/cancer drugs market share in 2017. This is due to the ability of targeted Therapeutics to kill only malignant cells, higher efficacy and higher survival rates associated with their use. The immunotherapy segment is expected to show fastest growth during the forecast period, registering a CAGR of 10.4%. This is attributed to surge in incidence of cancer worldwide and high unmet medical needs in some countries. Immunotherapy drugs are widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body which makes them less toxic as compared to other modes of cancer Therapeutics. Moreover, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types serves as a key factor for the growth of the oncology/cancer drugs market.
According to indication, the prostate cancer segment occupied the largest oncology/cancer drugs market share in 2017. This is due to presence of huge geriatric population. The lung cancer segment is expected to show fastest growth during the forecast period. This is due to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.
Asia-Pacific oncology/cancer drugs market possesses high growth potential, owing to rise in cancer awareness across the region and increase in R&D investment. Furthermore, this region presents notable opportunities for the venture capitalists and investors, as the developed markets are comparatively saturated. Moreover, increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers are some other factors, which contribute toward the growth of the oncology/cancer drugs market in this region. In addition, widespread prevalence of certain cancers, such stomach cancer, and presence of huge geriatric population in countries such as Japan drive the market growth in this region.
The report provides an extensive competitive analysis and profiles of the key market players such as AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, f. Hoffmann-La Roche ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc..The other players in the value chain include Sanofi, Amgen Inc. Bayer AG, and Exelixis, Inc.